SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Liraglutide-$^{13}C_5$,^{15}N TFA

Cat. No.: HY-P0014S1

Molecular Formula: $C_{167}{}^{13}C_5H_{265}N_{42}{}^{15}NO_{51}\cdot xC_2HF_3O_2$

Sequence: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-{Val-13C5,15N}-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-{Lys-N6-[N-(1-oxohexadecyl)-L-g-glutamyl]}-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly (TFA salt)



Sequence Shortening: HAEGTFTSD-{Val-13C5,15N}-SSYLGQAA-{Lys-N6-[N-(1-oxohexadecyl)-L-g-glutamyl]}-EFIAWLVRGRG (TFA salt)

Target: Isotope-Labeled Compounds

Pathway: Others

Storage: Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro	H_2O : 1 mg/mL (adjust pH to 10 with NH3·H2O)

BIOLOGICAL ACTIVITY

Description	Liraglutide-$^{13}C_5$,^{15}N (tetraTFA)is the ^{13}C and ^{15}N labeledLiraglutide(HY-P0014)[1]. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus[2].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA